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Abstract
A new series of pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine (PTP) derivatives has been
developed in order to explore their affinity and selectivity profile at the four adenosine recep-
tor subtypes. In particular, the PTP scaffold was conjugated at the C2 position with the 1-(3-
trifluoromethyl-benzyl)-1H-pyrazole, a group believed to confer potency and selectivity
toward the human (h) A2B adenosine receptor (AR) to the xanthine ligand 8-(1-(3-(trifluoro-
methyl)benzyl)-1H-pyrazol-4-yl)-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione (CVT 6975).
Interestingly, the synthesized compounds turned out to be inactive at the hA2B AR but they
displayed affinity at the hA3 AR in the nanomolar range. The best compound of the series
(6) shows both high affinity (hA3 AR Ki = 11 nM) and selectivity (A1/A3 and A2A/A3 > 9090;
A2B/A3 > 909) at the hA3 AR. To better rationalize these results, a molecular docking study
on the four AR subtypes was performed for all the synthesized compounds. In addition,
CTV 6975 and two close analogues have been subjected to the same molecular docking
protocol to investigate the role of the 1-(3-trifluoromethyl-benzyl)-1H-pyrazole on the bind-
ing at the four ARs.
Introduction
Adenosine is an ubiquitous modulator, which exerts its functions through interaction with
four G protein-coupled receptors classified as A1, A2A, A2B and A3 adenosine receptors (ARs).
[1,2] While A1, A2A and A3 ARs are stimulated by low concentrations of adenosine, the A2B
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subtype requires higher concentrations of the natural ligand. [3] In recent years, numerous
potent and selective ligands (agonists and antagonists) for the A1, A2A, A2B and A3 AR subtypes
have been discovered. [4,5] Some of them served as pharmacological tools and demonstrated
potential therapeutic applications in various pathological processes. For example, human (h)
A1 AR agonists are useful against cardiac arrhythmias and pain, while antagonists are beneficial
in kidney failure. Antagonists for the hA2A AR were widely studied for the treatment of Parkin-
son’s disease and other neurodegenerative disorders. [3–5] To date, the physio-pathological
role of the hA3 AR is controversial. This AR subtype is involved in cancer and inflammation,
although it is not yet clear whether blocking or activating this receptor would be therapeutic
for these conditions. [6] Identification of potent and selective ligands for the hA2B AR is diffi-
cult as compared with the other receptor subtypes. In addition, its characterization as a low-
affinity adenosine receptor led to the erroneous belief that the A2B AR was not of substantial
physiological relevance. [7–9] As a consequence, the hA2B AR is the least characterized among
the ARs, although in the last years, significant advances have been made in the understanding
of the molecular pharmacology and physiology of the hA2B ARs. [7–9] This subtype is highly
expressed during inflammatory and hypoxic conditions and, in these circumstances, adenosine
reaches very high extracellular concentrations necessary to activate the hA2B AR subtype. [9]
In fact, the hA2B ARs seem to be implicated in many different patho-physiological conditions
such as: asthma, [10–14] intestinal functions, vascular tone and permeability, ischemic precon-
ditioning, inflammation, angiogenesis and sickle disease. [9,15–20] Therefore, hA2B AR antag-
onists have been proposed as anti-asthmatic and/or anti-inflammatory agents. [4,5] In
particular, most of the so far developed hA2B AR antagonists are xanthine derivatives or ana-
logues. [21] In 2006 a very interesting compound named CVT 6975 (8-(1-(3-(trifluoromethyl)
benzyl)-1H-pyrazol-4-yl)-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione (1, Fig 1) proved to be
one of the most potent A2B AR antagonists ever reported. [22] In the non-xanthine family,
some adenine [23], 7-deazapurines [24], triazolo-triazine, [24] quinazoline, [25], triazinobenzi-
midazole [26], pyrimidine [27] and pyrazine [28] derivatives have been reported as hA2B AR
antagonists, but few of the synthesized compounds (e.g. pyrimidines) showed both significant
potency and selectivity for this receptor subtype.
In one of our research programs aimed at the identification of new non-xanthine hA2B AR
antagonists, we investigated variously substituted pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimi-
dine (PTP) derivatives. [29–31] A large number of derivatives with different substitutions at
the N7, N8 and N5 positions (see Fig 2 for numbering of the PTP ring system) have been pre-
pared, but unfortunately none of the synthesized compounds showed both affinity and selectiv-
ity at the hA2B ARs. [29–31] One of the most interesting compounds developed is derivative 2
(Fig 1), which displays good affinity for the hA2B AR (Ki = 165 nM) but it shows a greater affin-
ity towards the hA3 AR (Ki = 0.81 nM). [32] Taking into account these experimental observa-
tions, we decided to synthesize new derivatives by replacing the furan moiety in position C2 of
the PTP scaffold with the 1-(3-trifluoromethyl-benzyl)-1H-pyrazole-4-yl moiety present in the
CVT 6975 (1) with the aim to better explore the role of this position in the receptor recognition
and possibly obtain new A2B AR antagonists with non xanthinic structure (Fig 2).
Materials and Methods
Chemistry
General. Reactions were routinely monitored by thin-layer chromatography (TLC) on sil-
ica gel (precoated F254 Merck plates). Flash chromatography was performed using Merck 60–
200 mesh silica gel. Infrared spectra (IR) were measured on a Perkin Elmer 257 instrument.
1H-NMR were determined in CDCl3 or DMSO-d6 solutions with a Varian Gemini 200
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spectrometer, peaks positions are given in parts per million (δ) downfield relative to the central
peak of the solvent; J values are given in Hz. Melting points were determined on a Buchi-Tot-
toli instrument and are uncorrected. All reported products showed IR and 1H NMR spectra in
agreement with the assigned structures. Electrospray mass spectra were recorded on a ESI
Fig 1. CVT6975 (1) and the pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivative 2 as potent A2B
and A3 AR antagonists, respectively.
doi:10.1371/journal.pone.0143504.g001
Fig 2. Rational for the design of the target compounds 3–7.
doi:10.1371/journal.pone.0143504.g002
Hybridization between CVT 6975 and PTP Derivatives
PLOS ONE | DOI:10.1371/journal.pone.0143504 December 1, 2015 3 / 15
Bruker 4000 Esquire spectrometer and compounds were dissolved in methanol. Elemental
analyses were performed by the microanalytical laboratory of Dipartimento di Scienze Chi-
miche e Farmaceutiche, University of Trieste, and they were within ±0.4% of the theoretical
values for C, H and N. Light petroleum ether refers to the fractions boiling at 40–60°C. Organic
solutions were dried over anhydrous magnesium sulfate.
Synthesis of 1-(3-trifluoromethyl-benzyl)-1H-pyrazole-4-carboxylic acid hydrazide
(10). Pyrazole ester derivative 9 (5.7 g, 20 mmol) was dissolved in absolute ethanol (30 mL) and
an equivalent amount of hydrazine monohydrate (0.96 mL, 20 mmol) was added and the resulting
mixture was stirred at reflux for three days. The solvent was then removed in vacuo and the resi-
due crystallized from EtOAc to afford the corresponding hydrazide 9 as a white solid (mp 95°C)
in quantitative yield. IR (KBr): 3445–2960, 1690, 1650, 1610, 1480 cm-1; 1H NMR (CDCl3) δ: 3.65
(bs, 2H); 5.21 (s, 2H); 6.51 (bs, 1H); 7.21–7.58 (m, 4H); 7.66 (s, 1H); 7.77 (s, 1H). Anal. Calcd. for
C12H11N4OF3 (MW 284.24): C, 50.71; H, 3.90; N, 19.17. Found: C, 50.53; H, 3.85; N, 19.18.
Synthesis of 8-methyl-2-[1-(3-trifluoromethyl-benzyl)-1H-pyrazol-4-yl]-8H-pyrazolo
[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-ylamine (3). Pyrazole 8 (2.4 g, 20 mmol) was dis-
solved in diphenyl ether (30 mL) and hydrazide 10 (6.25 g, 22 mmol, 1.1 eq) was added. The
mixture was heated at 260°C using a Dean-Stark for the azeotropic elimination of water pro-
duced in the reaction. After 2.5 h, the mixture was poured onto hexane (200 mL) and cooled.
The precipitate of crude pyrazole-triazole derivative 11 was filtered off, and utilized for the
next step without further purifications. The crude residue, was dissolved in N-methyl pyrroli-
done (40 mL), cyanamide (3 eq, 60 mmol, 2.5 g) and p-toluen sulfonic acid (1.5 eq, 30 mmol,
5.7 g) were added and the mixture was heated at 160°C for 4 h. Cyanamide (3 eq, 60 mmol, 2.5
g) was added again and the solution was heated overnight. Then the solution was diluted with
EtOAc (80 mL) and the precipitate (excess of cyanamide) was filtered off; the filtrate was con-
centrated under reduced pressure and washed with water (3 x 30 mL). The organic layer was
dried (Na2SO4) and evaporated under vacuum. The residue was purified by flash chromatogra-
phy (EtOAc/Methanol 9.5:0.5) to afford the desired compound 3 in a good overall yield (60%)
as a yellow solid. Mp 125°C (EtOAc-light petroleum); IR (KBr): 3330–2960, 1640, 1605, 1550,
1450 cm-1; 1H NMR (DMSO-d6) δ: 3.87 (s, 3H); 5.20 (s, 2H); 5.72 (bs, 2H); 7.18–7.41 (m, 4H);
7.84 (s, 1H); 7.96 (s, 1H); 7.97 (s, 1H). ES-MS: (MH+) 414.4. Anal. Calcd. for C18H14N9F3
(MW 413.36): C, 52.30; H, 3.41; N, 30.50. Found: C, 52.13; H, 3.44; N, 30.38.
Synthesis of 1-{8-Methyl-2-[1-(3-trifluoromethyl-benzyl)-1H-pyrazol-4-yl]-8H-pyrazolo
[4,3-e][1,2,4]triazolo [1,5-c]pyrimidin-5-yl}-3-phenylurea (4). Amino compound (3) (206
mg, 0.5 mmol) was dissolved in freshly distilled dioxane (15 mL) and phenyl isocyanate
(130 μL, 1 mmol, 2 eq) was added. The mixture was refluxed under argon for 18 hours. Then
the solvent was removed under reduced pressure and the residue was purified by flash chroma-
tography (EtOAc-light petroleum 8:2) to afford the desired compound 4 in a good yield (88%)
as a white solid, mp 180°C (EtOAc-light petroleum); IR (KBr): 3355–2980, 1705, 1655, 1600,
1530 cm-1; 1H NMR (CDCl3) δ: 3.97 (s, 3H); 5.22 (s, 2H); 7.01–7.42 (m, 9H); 7.88 (s, 1H); 7.98
(s, 1H); 7.99 (s, 1H); 8.30 (bs, 1H); 10.93 (bs, 1H). ES-MS: (MH+) 533.1. Anal. Calcd. for
C25H19N10OF3 (MW 532.48): C, 56.39; H, 3.60; N, 26.30. Found: C, 56.53; H, 3.62; N, 26.48.
General procedure for acylation of amino group at the 5 position (5–7). Amino com-
pound 3 (206 mg, 0.5 mmol) was dissolved in freshly distilled dioxane (15 ml) and the appro-
priate acyl chloride (1 mmol) and triethylamine (1 mmol, 140 μL) were added. The mixture
was refluxed under argon for 18 hours. Then the solvent was removed under reduced pressure
and the residue was dissolved in EtOAc (30 ml) and washed twice with water (15 ml). The
organic phase was dried on anhydrous Na2SO4 and concentrated under reduced pressure. The
residue was purified by flash chromatography (EtOAc-light petroleum 8:2) to afford the
desired compounds (5–7).
Hybridization between CVT 6975 and PTP Derivatives
PLOS ONE | DOI:10.1371/journal.pone.0143504 December 1, 2015 4 / 15
N-{8-Methyl-2-[1-(3-trifluoromethyl-benzyl)-1H-pyrazol-4-yl]-8H-pyrazolo[4,3-e][1,2,4]
triazolo[1,5-c]pyrimidin-5-yl}-benzamide (5): Yield 85%, pale yellow solid; mp 115°C (EtOAc-
light petroleum); IR (KBr): 3240–2995, 1685, 1635, 1570, 1525 cm-1; 1H NMR (CDCl3) δ: 3.96
(s, 3H); 5.22 (s, 2H); 7.08–7.55 (m, 9H); 7.85 (s, 1H); 7.94 (s, 1H); 7.97 (s, 1H); 9.41 (bs, 1H).
ES-MS: (MH+) 518.2. Anal. Calcd. for C25H18N9OF3 (MW 517.47): C, 58.03; H, 3.51; N, 24.36.
Found: C, 57.92; H, 3.44; N, 24.18.
N-{8-Methyl-2-[1-(3-trifluoromethyl-benzyl)-1H-pyrazol-4-yl]-8H-pyrazolo[4,3-e][1,2,4]
triazolo[1,5-c]pyrimidin-5-yl}-phenyl-acetamide (6): Yield 85%, white solid; mp 190°C (EtOAc-
light petroleum); IR (KBr): 3240–2990, 1675, 1605, 1580, 1525 cm-1; 1H NMR (CDCl3) δ: 3.96
(s, 3H); 4.27 (s, 2H); 5.20 (s, 2H); 7.03–7.37 (m, 9H); 7.82 (s, 1H); 7.94 (s, 1H); 7.97 (s, 1H);
8.82 (bs, 1H). ES-MS: (MH+) 518.2. Anal. Calcd. for C26H20N9OF3 (MW 531.49): C, 58.76; H,
3.79; N, 23.72. Found: C, 58.93; H, 3.65; N, 23.88.
2-(4-Methoxy-phenyl)-N-{8-Methyl-2-[1-(3-trifluoromethyl-benzyl)-1H-pyrazol-4-yl]-8H-
pyrazolo[4,3-e] [1,2,4]triazolo[1,5-c]pyrimidin-5-yl}-phenyl-acetamide (7): Yield 77%, yellow
solid; mp 178°C (EtOAc-light petroleum); IR (KBr): 3245–2975, 1680, 1615, 1570, 1515 cm-1;
1H NMR (CDCl3) δ: 3.97 (s, 3H); 4.18 (s, 3H); 4.25 (s, 2H); 5.21 (s, 2H); 7.03–7.37 (m, 6H);
7.57 (d, 2H, J = 9); 7.83 (s, 1H); 7.96 (s, 1H); 7.98 (s, 1H); 8.78 (bs, 1H). ES-MS: (MH+) 562.2.
Anal. Calcd. for C27H22N9O2F3 (MW 561.52): C, 57.75; H, 3.95; N, 22.45. Found: C, 57.53; H,
3.86; N, 22.33.
Biology
All pharmacological methods followed the procedures as described earlier. [33–36] In brief,
membranes for radioligand binding were prepared from CHO cells stably transfected with
human AR subtypes in a two-step procedure. In a first low-speed step (1,000 x g) cell fragments
and nuclei were removed. The crude membrane fraction was sedimented from the supernatant
at 100,000 x g. The membrane pellet was resuspended in the buffer used for the respective
binding experiments (50 mM Tris/HCl buffer pH 7.4 for hA1 and hA2A AR; 50 mM Tris/HCl,
10 mMMgCl2, 1 mM EDTA, pH 8.25 for hA3 AR), frozen in liquid nitrogen and stored at
-80°C. For the measurement of adenylyl cyclase activity only one high speed centrifugation of
the homogenate was used. The resulting crude membrane pellet was resuspended in 50 mM
Tris/HCl, pH 7.4 and immediately used for the cyclase assay.
For radioligand binding at human A1 ARs 1 nM [
3H]CCPA was used (KD = 0.61 nM),
whereas 10 nM [3H]NECA were used for A2A (KD = 20.1 nM). The high-affinity agonist [
3H]
HEMADO (KD = 1.1 nM) was used for A3 AR binding at a concentration of 1 nM. Non specific
binding of [3H]CCPA was determined in the presence of 1 mM theophylline, in the case of
[3H]NECA and [3H]HEMADO, 100 μMR-PIA was used. Ki-values from competition experi-
ments were calculated with the program SCTFIT. [33–35]
Radioligand binding at human A2B ARs is problematic as no high-affinity radioligand is
commercially available for this subtype. Therefore, inhibition of NECA-stimulated adenylyl
cyclase activity (stimulation with 5 μM of NECA, EC50 = 2.4 μM) was determined as a measure-
ment of affinity of compounds. The procedure was carried out as described previously with
minor modifications. [33–35] Membranes were incubated with about 150,000 cpm of [α-32P]
ATP for 20 min in the incubation mixture as described without EDTA and NaCl. [33–35]
Molecular modeling
The models for human A1, A2A, A2B and A3 ARs were retrieved from the Adenosiland platform
(http://mms.dsfarm.unipd.it/Adenosiland) [36], selecting the crystallographic structure of
hA2A AR, in complex with the high affinity antagonist ZM241385 (PDB access code: 4EIY;
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resolution 1.8 Å), as template for homology modelling. [37] The numbering of the amino acids
follows the arbitrary scheme by Ballesteros andWeinstein: each amino acid identifier starts
with the helix number, followed by the position relative to a reference residue among the most
conserved amino acids in that helix, to which the number 50 is arbitrarily assigned. [38]
Ligand conformations were built using the MOE-builder tool implemented in the MOE
suite [39] and were subjected to a MMFF94x energy minimization until the rmsd conjugate
gradient was<0.05 kcal mol–1 Å–1. All antagonists were docked into the hypothetical TM
binding site of the hA3 AR model derived from the centre of mass of the ZM241385 inhibitor.
The workflow of the molecular docking approach used in the present work has been previously
reported. [40] Molecular docking study was performed employing the docking tool of the
GOLD Suite v5.2.1. [41] For each compound, 25 independent docking runs were performed
and searching was conducted within a user-specified docking sphere with the Genetic Algo-
rithm protocol and the GoldScore scoring function. The resulting docking complexes (ligand
and side-chain residues within 4.5 Å) were subjected to a MMFF94x energy minimization until
the rms conjugate gradient was<1 kcal mol–1 Å–1.
Analyses of docking poses and quantitative analysis for nonbonded intermolecular interac-
tions (H-bonds, hydrophobic, electrostatic) were calculated and visualized using MOE suite.
[39] To estimate the electrostatic contributions, atomic charges for the ligands were calculated
with MOPAC-2012 [42] and the PM3/ESP methodology, whereas partial charges for the pro-
tein amino acids were computed with the AMBER99 force field. The validation of the proposed
docking protocol has been previously published. [43] Physicochemical and ADME properties
of references and newly synthesized compounds were calculated with StarDropTM, version
6.0. [44]
Results and Discussion
Chemistry
Compounds 3–7 were prepared following the general synthetic strategy summarized in Fig 3.
They were synthesized according to a well-known procedure for the synthesis of the PTPs, pre-
viously reported. [45–47]
Reaction of the N2-methyl-4-cyano-5-amino pyrazole 8 with the hydrazide derivative 10
(prepared from the corresponding ester 9 [22] by reaction with hydrazine monohydrate in
absolute ethanol at reflux for three days) in diphenyl ether at 260°C led to the aminotriazole
11, which was in turn converted, without any further purification, into the final compound 3
by reaction with cyanamide in the presence of p-toluen sulfonic acid. Amido derivatives 5–7
were obtained by reaction of the amino compound 3 with the appropriate acyl halide in diox-
ane at reflux in the presence of triethylamine, while the ureido derivative 4 was obtained by
reaction of the amino compound 3 with phenyl isocyanate in dioxane at reflux (Fig 3).
Biological activity
Newly synthesized compounds (3–7) were tested at the human A1, A2A, A2B and A3 ARs
expressed in CHO (Chinese Hamster Ovary) cells. [3H]CCPA ([3H]2-Chloro-N6-cyclopentyla-
denosine) (hA1 AR), [
3H]NECA ([3H]5'-N-ethylcarboxamidoadenosine) (hA2A AR) and [
3H]
HEMADO ([3H]2-(1-Hexynyl)-N-methyladenosine) (hA3 ARs) were used as radioligands in
binding assays. Inhibition of NECA-stimulated adenylyl cyclase activity in CHO cells express-
ing hA2B receptors was determined as a measurement of affinity of compounds at the hA2B AR
(Fig 4). [33–35]
As clearly depicted in Fig 4, surprisingly all novel CVT-like compounds do not show appre-
ciable activity at the hA2B AR. On the contrary they have shown an unexpected high affinity,
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with some in the nanomolar range, towards the hA3 AR subtype. In S1 Fig representative com-
petition curves for the hA3 selective agonist [
3H]HEMADO (total binding) from single experi-
ments for compounds 6 and 4, respectively, are reported. The affinity at the hA3 AR seems to
be more related to the substitution at the N5 position than to the substituent present at the C2
position. In fact, the N5-unsubstituted derivative 3, proved to be almost inactive at all four
ARs, while, the introduction of a substituent at the N5 position (4,7) induced a recovery of
affinity at the hA3 AR with good levels of selectivity versus the other receptor subtypes. In par-
ticular, the introduction of an arylcarbamoyl moiety, which has been demonstrated optimal
substituent for the hA3 AR, [29–32,45–48] led to compound 4, which shows a Ki value of 46.7
nM with a 50–70 fold selectivity versus the other receptor subtypes. The most potent com-
pound of this series (6) is the derivative bearing a phenylacetyl moiety at the N5 position which
shows a Ki value of 11.1 nM and high selectivity (hA1/hA3 and hA2A/hA3>9090; hA2B/hA3
>909) over the other receptor subtypes. Introduction of a methoxy group on the para position
of phenyl ring (7) leads to a reduction of affinity of about 5 fold (hA3 AR Ki = 53.0 nM) with a
consequent reduction of selectivity, while the replacement of phenylacetyl group with a benzoyl
moiety (5) considerably reduces both affinity and selectivity at the hA3 AR.
Regarding the C2 position, in a previous work it has been demonstrated that the substitu-
tion of the furyl ring at the C2 position of the PTP scaffold with a phenyl moiety gives deriva-
tives which maintained high affinity at the hA3 AR and showed improved selectivity at this AR
subtype. [48] Moreover, with this work we have demonstrated that at the hA3 AR bigger sub-
stituents than five or six-membered aromatic rings, such as the long chain of 1-benzyl-1H-
Fig 3. Synthesis of desired compounds 3–7. Reagents: i: NH2NH2
.H2O, EtOH, reflux, 3 days; ii: Ph2O, 260°C, 2.5 h; iii: NH2CN, pTsOH, 160°C, 4 h; iv:
PhNCO, dioxane, reflux; v: RCOCl, Et3N, dioxane, reflux.
doi:10.1371/journal.pone.0143504.g003
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pyrazole, are also tolerated. Obviously, this short series of compounds does not allow us to out-
line a structure activity relationship (SAR) analysis. In addition, the obtained results are consis-
tent with the well-known SAR of PTP derivatives at the hA3AR, that is: at the N5 position a
substitution on the amino group is preferred and, in particular, phenylacetamido moieties are
better than benzamido moieties; whereas, at the C2 position, the substitution of the furyl ring
enhances selectivity versus the other receptor subtypes. [29–32,45–48] It is worth to remember
that although no A3 AR antagonist has still reached clinical trials, there are several pharmaco-
logical evidences that suggest their potential use for the treatment of asthma, chronic obstruc-
tive pulmonary disease (COPD), neurodegenerative diseases, stroke, glaucoma and cancer. [6]
Consequently there is an ongoing interest in the development of novel potent and selective
antagonists for the A3 AR subtype.
Computational studies
To better rationalize these unexpected experimental results, a molecular docking study on the
four hAR subtypes was performed. The workflow of the molecular docking approach used in
the present work has been previously reported. [40,49] First of all, the role of the 1-(3-trifluoro-
methyl-benzyl)-1H-pyrazole-4-yl moiety in receptor recognition has been investigated starting
from the analysis of the hypothetical binding mode of CTV 6975 (1) and two other structurally
similar analogues 36 and 33 [22] against all four AR subtypes (Fig 5A). In particular, com-
pound 36 differs in the 1,3-disubstitution of the xanthine core, where the methyl groups of
Fig 4. Structures and binding profile of reference (1,2,33,36) and synthesized compounds (3–7). aDisplacement of specific [3H]-CCPA binding at hA1
ARs expressed in CHO cells, (n = 3–6). bDisplacement of specific [3H]-NECA binding at hA2A ARs expressed in CHO cells.
cKi values of the inhibition of
NECA-stimulated adenylyl cyclase activity in CHO cells expressing hA2B ARs.
dDisplacement of specific [3H]-HEMADO binding at hA3 ARs expressed in
CHO cells. Data are expressed as geometric means, with 95% confidence limits. edata from ref. [22]. fdata from ref. [32].
doi:10.1371/journal.pone.0143504.g004
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CVT 6975 (1) are replaced by two propyl groups. Compound 33 shares the same substituents
on the xanthine core with 36 with the trifluoromethyl group being replaced by a fluorine atom.
Both compounds retain a notable affinity for the hA2B AR (Ki = 14 nM) but a lower selectivity
towards the other subtypes (36: hA1 AR Ki = 170 nM; hA2A AR Ki = 400 nM; hA3 AR Ki = 150
nM, 33: hA1 AR Ki = 170 nM; hA2A AR Ki = 230 nM; hA3 AR Ki = 56 nM). [22]
Molecular docking results suggest for the three CVT analogues (1, 36, 33) an univocal binding
mode into the putative orthosteric pocket of the hA2B AR with the xanthine core faced to the key
residue Asn254 (6.55) and sided by Phe173 (EL2), Val250 (6.51) and Ile276 (7.39) (Fig 5B). The
1-benzyl-1H-pyrazole moiety whether substituted with trifluoromethyl or fluorine atom interacts
with Met272 (7.35) and with residues located in EL2, namely Leu172-Glu174. As an example,
the hypothetical binding mode of compound 36 at the hA2B AR is reported in Fig 5B. Interest-
ingly, the docking results of compound 36 at the hA1, hA2A and hA3 ARs confirm a similar rec-
ognition pathway to that observed for the A2B AR (Fig 5B). In particular, the xanthine core is
positioned closely to that observed for two other xanthinic ligands, caffeine and XAC, in their
crystallographic bound state at the hA2A AR (PDB codes 3RFM and 3REY, respectively). [50]
Moreover, molecular docking results suggest a crucial role of the 1-benzyl-1H-pyrazole moiety
in increasing the binding affinity against all the receptor subtypes, while the nature of the
Fig 5. Bindingmode of xanthine-based compounds at the four AR subtypes. Compound 36, in dark green, was selected as reference to show the
proposed binding mode at the four AR subtypes. The crystallographic coordinates of caffeine, in magenta, bound to hA2A AR are reported superimposed to
the binding mode of compound 36. The xanthine core of compound 36 is oriented in a similar manner to the crystallographic data. Residues particularly
important in the binding are reported as light grey sticks.
doi:10.1371/journal.pone.0143504.g005
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1,3-disubstitution at the xanthine core seems to play a role in determining the ligand selectivity
profile. In fact, the presence of larger substituents in 1,3 positions, such as propyl groups, seems
to be well tolerated at the hA1, hA2A and hA3 ARs while at the hA2B AR the 1,3-dimethyl substi-
tution seems to guarantee the best shape complementarity in the orthosteric binding pocket.
Secondly, all newly synthesized analogues were subjected to the same docking protocol. In
particular, at the hA3 AR all compounds 4–7 showed an appreciable receptor complementarity
even if two distinct plausible binding modes are detected (hereafter named A and B) analyzing
all docking poses. In the binding mode A, the 1-benzyl-1H-pyrazole moiety is placed similarly
to the CVT-like compounds previously described, with these specific interacting residues:
Gln167 (EL2), Leu264 (7.35), Tyr265 (7.36). The substituent at the N5 position is inserted in
an accessory pocket defined by Ser181 (5.42), Leu246 (6.51) and Ser247 (6.52). This pocket is
located deeper in the TM bundle, under the Asn250 (6.51), and it is delimited by TM3 and
TM5 and by Trp243 (6.48). Interestingly, this accessory pocket is probably the most relevant
structural difference among the hypothetical binding sites of the AR subtypes. In particular,
the Ser247 (6.52) in the hA3 AR is not conserved in the other subtypes, replaced by an histidine
in the other subtypes. This mutation significantly perturbs the shape and the of the hA3 AR
orthosteric binding pocket compared to those of all the other subtypes. More interestingly, this
histidine has been reported to participate in both agonist and antagonist binding to the hA2A
AR by mutagenesis studies. [51,52] Also Ser181 (5.42) is a peculiarity of the hA3 AR being
replaced by conserved asparagine in the other AR subtypes.
However, in the hypothetical binding mode A the Asn250 (6.55) residue is not directly involved
in the interaction with the compounds (4–7), although a water-mediated interaction could not be
excluded. As an instance of binding mode A the pose of most potent analogue (6) is shown in Fig
6A, while the superposition of the receptor complex for 36 and 6 is reported in S4 Fig.
In the binding mode B, the position of the substituent at the C2 and N5 positions is inverted,
while the orientations of the PTP core and of the methyl at N8 position are retained in the
same region occupied in the binding mode A (Fig 6B and S4B Fig). The two distinct poses
show similar interactions networks as demonstrated by comparing the Interaction Energy (IE)
plots where the per-residue electrostatic and hydrophobic contributions are calculated (S4C
Fig). Even a more quantitative comparison of the IE contributions for the most important resi-
dues reveals similar profile (Fig 6C). On the contrary, all analogues when docked into hA1,
hA2A and hA2B ARs did not show a stabilized binding pose comparable to those observed for
the hA3 AR. In particular compounds 4–7, that are characterized by large substituents in both
C2 and N5 positions, seem not to be able to occupy the accessory pocked that we have previ-
ously described characterizing the orthosteric binding site of the hA3 AR. Also in this case, the
analysis of the Interaction Energy (IE) plots supports the hypothesis of the complementary
lacking when compounds 4–7 interact with hA1, hA2A and hA2B ARs. Again, the most relevant
difference can ascribed to the missing interaction with the residues delimiting the accessory
cavity, as shown in S5 Fig.
The physicochemical and ADME (absorption, distribution, metabolism, and excretion)
properties of the newly synthesized compounds (3–7) were calculated in silico and compared
to those calculated for CVT-like derivatives and reference hA3 AR antagonists recently
reviewed by Borea et al. (S1 Table). [53] The PTP scaffold in comparison to the xanthine core
shows a deterioration of the pharmacokinetic (PK) profile. In particular, the partition coeffi-
cient cLogP (4.49 and 2.87 for compound 6 and CVT 6975 (1), respectively) and the solubility
are affected. Nevertheless, compound 6 and CVT 6975 (1) present similar ADME properties.
The limitations in the pharmacokinetic profile is a common issue for the selective hA3 AR
antagonists already reported in literature. With only few exceptions, the gain in selectivity over
the other human ARs subtypes is associated with a PK profile deterioration.
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Conclusions
We have presented a novel series of pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines bearing a
1-(3-trifluoromethyl-benzyl)1H-pyrazol-4-yl moiety at the C2 position in order to explore the
effect on affinity and selectivity profiles at the four ARs. In particular, the 1-(3-trifluoromethyl-
benzyl)1H-pyrazol-4-yl group when attached at the 8 position of xanthine derivatives, such as
CVT-6975 (1), is known to confer high affinity for the hA2B AR. Curiously, the synthesized
Fig 6. Bindingmode of compound 6 at the hA3 AR. (A) (B) Hypothetical binding mode A and B of newly synthetized compounds to hA3 AR. The most
potent derivative, 6, was selected as example and is represented as orange stick. Subsets of hA3 AR residues, involved in the binding, are coloured in light
grey. (C) The electrostatic and hydrophobic contributes to interaction energy calculated for the residue mostly involved in the binding are reported compound
6 in the conformation reported in panel A (in red) and B (in blue). Electrostatic energy values are expressed in kcal mol–1, whereas hydrophobic scores are
expressed in arbitrary hydrophobic units.
doi:10.1371/journal.pone.0143504.g006
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compounds were inactive at the hA2B AR but demonstrated activity as potent and selective
antagonist of the hA3 AR. A molecular docking study was performed in order to rationalize the
influence of a 1-(3-trifluoromethyl-benzyl)-1H-pyrazole branch. We observed that only the
hA3 AR has the topological features to accommodate this new series in agreement with experi-
mental data. Interestingly, the ability to host such a big moiety can be ascribed to an accessory
binding pocket present in the hA3 AR, which is formed by specific unconserved residues. Two
possible binding modes were proposed in which the substituents in C2 and N5 are reciprocally
inverted. Further studies will be needed to validate which one is predominant or if they may
co-exist. Although derivatives more potent at the hA3 AR, and with a better drug-like proper-
ties than compound 6, have been already reported in literature, our derivative shows high selec-
tivity for hA3 AR over the other ARs subtypes (S1 Table), which is comparable to other
selective antagonists already reported. [53] More interestingly, the high affinity obtained by
introducing long chains, such as a benzyl-1H-pyrazole, at the C2 position, opens to new possi-
bilities in the development of new derivatives bearing PTP or PTP-derived simplified scaffolds.
In addition, in the binding mode A, the chain at the C2 position is directed to the solvent
exposed area of the hA3 AR binding pocket, suggesting a new anchoring point for further
derivatization (e.g. with fluorophore for detection purposes).
Supporting Information
S1 Fig. Competition of compounds 6 and 4 for A3 receptor binding. Both compounds show
high affinity binding to hA3 ARs as shown by competition for the A3 selective agonist [
3H]
HEMADO. Representative curves (total binding) from single experiments with Ki values of 17
and 39 nM for compounds 6 and 4, respectively, are reported.
(PDF)
S2 Fig. Competition of compound 3 for A1 receptor binding. Compound 3 shows in a radi-
oligand competition assay with the A1 selective radioligand [
3H]CCPA a Ki value of 764 nM.
The curve shows total binding to hA1 ARs from a representative single experiment.
(PDF)
S3 Fig. Competition of compound 3 for A2A receptor binding. Compound 3 shows in a radi-
oligand competition assay with the nonselective radioligand [3H]NECA a Ki value of 6820 nM.
The curve shows total binding to hA2A ARs from a representative single experiment.
(PDF)
S4 Fig. Hypothetical binding modes of compound 6 superimposed to compound 36 at the
hA3 AR and electrostatic and hydrophobic contributions maps for compound 6. The hypo-
thetical binding modes (A and B respectively indicated) of compound 6 are reported super-
posed to the coordinates of compound 36 to reveal the similarity in the accommodation of the
common 1-(3-Trifluoromethyl-benzyl)-1H-pyrazole residue. The coordinates of compound 36
in B are obtained from a secondary docking solution. (C) Per residue electrostatic interaction
energy map and per residue hydrophobic interaction score map. The maps are calculated for a
selected pose of compound 6 inside the hA3 AR binding site. Electrostatic energy values are
expressed in kcal mol–1, whereas hydrophobic scores are expressed in arbitrary hydrophobic
units.
(TIF)
S5 Fig. Comparison of the contribution to the docking score of the key residue for the bind-
ing of compound 6 to hA3 AR according molecular docking studies. The contributes to elec-
trostatic and hydrophobic energy interactions for hA1, hA2A, hA2B and hA3 ARs are reported
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in panels A, B, C and D respectively. In panel D, the profiles of the two predominant binding
modes for hA3 AR, A (red) and B (blue), are showed. In Panel E the location of residues Met86,
Ser181, Ser247 and Asn250 (in cyan) and Phe168, Trp243, Leu246 and Tyr265 (in green) in
the A3 AR and the corresponding residues in the others AR subtypes is indicated by the ball
representation of alpha Carbon atoms.
(TIF)
S1 Table. Selectivity profile and predicted physicochemical and ADME properties of refer-
ences and newly synthesized compounds (3–7).
(DOCX)
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